Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
Welcome back, everyone, to the 4th Annual H.C. Wainwright HBV Conference. My name is Patrick Trucchio. I'm a senior healthcare analyst at H.C. Wainwright. It's my pleasure to introduce our next speaker, Cassie Gorsuch, VP of Gene Therapy at Precision BioSciences, an advanced gene editing company dedicated to improving life with the novel ARCUS genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure.
So with that, let's start with some background on the ARCUS platform, history of its development, and data that's been generated to date that underpins the in vivo gene editing pipeline.
Yeah. Thanks, Patrick. Thanks for having me here today.
So as you mentioned, Precision is a gene editing company. So we are developing proprietary gene editors that we call ARCUS nucleases. And so these nucleases are really differentiated from a lot of the other nucleases in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
